Global General Anxiety Disorder Market worth USD xx billion by 2027

The Market Statsville Group (MSG) publishes the new report on the "General Anxiety Disorder Market by Therapies Type (Interpersonal Therapy (IPT), Behaviour Therapy, Cognitive Behavioral Therapy (CBT), and Mindfulness-based Cognitive Therapy (MBCT)), By Medical devices Type, (Deep Brain Stimulation (DBS), Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), and  Vagus Nerve Stimulation (VNS)), By Therapeutics (Antidepressant, Buspirone, And Benzodiazepines), and Region - Global Trends, Market Share, and Forecast to 2027". The global general anxiety disorder market is estimated to grow from USD xx billion in 2020 to USD xx billion by 2027, at a CAGR of 5.1% from 2021 to 2027. The rising prevalence of mental health disorders worldwide and emerging markets are driving this market's growth. However, the prevalence of personality disorders and stress, particularly in adults, is increasing, as are global awareness campaigns and media and an increase in the female adult population. However, the global general anxiety disorder market may be hampered by a lack of patient awareness and self-medication. Anxiety disorder is a complicated mental health condition that frequently necessitates medical and psychiatric intervention.

Anxiety is a normal part of life occasionally, but people who experience anxiety regularly with intense, excessive, and persistent worry and fear about everyday situations are diagnosed with disorders. It begins with panic attacks, which are brief episodes of severe anxiety, fear, or terror that peak within minutes. Besides, the main growth opportunities for the anxiety disorder treatment market are an increasing geriatric population combined with changing lifestyles. In the United States, a large portion of the population is over the age of 65. Studies have shown that as a person's age rises, they risk developing mental illness. They are more prone to mental illnesses. Another growth opportunity is the rapid advancement of technology.

Global General Anxiety Disorder Market Segmentation

The general anxiety disorder market has been segmented into the Therapies type, therapeutics, medical devices type, and region.

• By Therapies Type (Interpersonal Therapy (IPT), Behaviour Therapy, Cognitive Behavioral Therapy (CBT), and Mindfulness-based Cognitive Therapy (MBCT))
• By Medical Devices Type (Deep Brain Stimulation (DBS), Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), and  Vagus Nerve Stimulation (VNS))
• By Therapeutics (Antidepressant, Buspirone, And Benzodiazepines)
• By Region (US, Canada, Mexico, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Southeast Asia, Australia, Saudi Arabia, UAE, South Africa, Qatar, Nigeria, Israel, Brazil, Argentina, Peru)

Cognitive Behavioral Therapy (CBT), by therapies type, is estimated to hold the largest market share during the forecast period

The global general anxiety disorder market is segmented into Interpersonal Therapy (IPT), Behaviour Therapy, Cognitive Behavioral Therapy (CBT), and Mindfulness-based Cognitive Therapy (MBCT) based on the therapies type. The Cognitive Behavioral Therapy (CBT) segment generated the highest revenue in 2020, and it is expected to register a significant CAGR from 2020 to 2027. For generalized anxiety disorder, cognitive behavioral therapy is the most effective form of psychotherapy. Cognitive-behavioral therapy (CBT) is a psychosocial intervention aimed at enhancing mental health. CBT focuses on challenging and changing cognitive distortions and behaviors, improving emotional regulation, and developing personal coping strategies to address current issues.

Don't miss out on business opportunities in General Anxiety Disorder Market. Speak to our research analyst and gain crucial market insights that will benefit your business growth.

North America accounts for the highest market share during the forecast period in the General Anxiety Disorder market

Based on the regions, the global general anxiety disorder market has segmented North America, Asia-Pacific, Europe, South America, and the Middle East & Africa. In North America, three main countries, the US, Mexico, and Canada, are analyzed. The United States has the largest share of the market, followed by Canada. Both countries have heavily invested in the development of drugs for GAD treatment. With the adoption of sedentary lifestyles, the number of depression cases in Canada is likely to rise. This has accelerated the development of therapeutics, and it is more likely to positively impact the market for generalized anxiety disorder demand and growth. The rise in GAD diagnoses in this region can be attributed to improvements in mental healthcare services and increased awareness of anxiety disorders. The growing geriatric population in Mexico is driving up anxiety diagnosis rates and demand for physiotherapies like Cognitive Behavior Therapy (CBT) and GAD medication.

Furthermore, the market is expanding as the prevalence of anxiety disorders rises, and people become more aware of the issue. During the forecast period, it is expected to maintain its position. According to the National Institute of Mental Health, GAD affects at least 6.8 million adults in the United States each year, or 3.1 percent of the population.

This research report includes a study on the development and marketing strategies, product portfolios, and winning design of the leading companies operating in the general anxiety disorder market. It also consists of leading companies such as GlaxoSmithKline Pharmaceuticals Limited, Bristol-Myers Squibb, Noven Pharmaceuticals, Inc., Actavis Pharmaceutical Company, F. Hoffmann-La Roche, Abbott Laboratories, and Eli Lilly and Company, among others. These market players have focused on acquisitions and expansion to gain a larger market share in the General Anxiety Disorder market. For instance, in November 2021, Bionomics Limited, a clinical-stage biopharmaceutical company, announced that it had received FDA approval to proceed with a Phase 2 clinical trial called the PREVAIL Study to evaluate its lead clinical compound, BNC210, for the acute treatment of Social Anxiety Disorder (SAD). BNC210 is a proprietary oral selective negative allosteric modulator of the nicotinic acetylcholine receptor seven developed for the acute and chronic treatment of SAD and Post-Traumatic Stress Disorder (PTSD). Following positive results in a previous Phase 2a study in GAD patients, where a single oral dose of BNC210 significantly reduced connectivity between the amygdala and the anterior cingulate cortex, a network involved in regulating anxious responses to aversive stimuli, BNC210 will now be tested as an acute, or single-dose, treatment for patients with SAD. Thus, the clinical trial and drugs approvals have risen, which has driven the market growth.

Browse complete report: https://www.marketstatsville.com/general-anxiety-disorder-market

About Market Statsville Group

Market Statsville Group (MSG) is a business research and consulting platform of Statsville Consulting Private Limited, based in Oklahoma, USA. MSG is the leading market research and strategy builder with the depth and breadth of solutions that perfectly suit your every need. MSG provides solutions in a wide range of industry verticals in market sizing, analysis, and intelligent business insights. MSG has experienced research analysts who are proficient at digging deep and providing various customizable data that help you make decisions with clarity, confidence, and impact. Furthermore, Market Statsville Group already benefited more than 1,000 companies each year for their revenue planning. It helped them take their disruptions/innovations early to the market by providing them research ahead of the curve.

MSG has an entire repository of research reports on more than 1,000 niche industries, 3,000 high-growth potential markets, 5,000 data sets, and more than 12,000 company profiles.

Contact Us:

Market Statsville Group

416, East Standsberry Street, Perkins, Oklahoma 74059, USA

USA: +1-580-205-2707 | +91 702 496 8807

Email: sales@marketstatsville.com

Web: www.marketstatsville.com